Professionals en links

This page is only for professionals. Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a systemic disorder characterized by progressive cyst formation in both kidneys, with progressive kidney enlargement often leading to end stage renal disease. Progressive cyst formation is also found in the liver in a majority of patients.
Our consortium consists of 4 teams (University Medical Centers from Leiden, Rotterdam, Nijmegen and Groningen)  and includes clinical as well as basic science researchers. The consortium investigates ADPKD with 3 major aims:

  • Experimental studies using Pkd1-mutant mouse models
  • Development of biomarkers for predicting disease progression and assessing treatment response in ADPKD
  • Perform the DIPAK1 study, a randomized, controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in ADPKD. This study is closed and published at

Below you can find research output of our consortium. If you have any scientific questions, questions regarding patient care, or want to come into contact with our consortium, please contact Dorien Peters,, Primary Investigator of the DIPAK consortium (senior researcher at the LUMC) or Esther Meijer,, (internist-nephrologist at the UMCG).

Scientific publications

Salih,M., Demmers,J.A., Bezstarosti,K., Leonhard,W.N., Losekoot,M., van Kooten,C., Gansevoort,R.T., Peters,D.J.,Zietse,R., Hoorn,E.J. (2016) Proteomics of Urinary Vesicles Links Plakins and Complement to Polycystic Kidney Disease. J. Am. Soc. Nephrol., 27, 3079‐3092. DOI: 10.1681/ASN.2015090994;;

Casteleijn,N.F., Gansevoort,R.T., Leliveld,A.M. (2016) Nephrectomy in patients with autosomal dominant polycystic kidney disease, does size matter? World J. Urol., 34, 907‐908. DOI: 10.1007/s00345‐016‐1799‐1

Neijenhuis MK, Gevers TJ, Hogan MC, Kamath PS, Wijnands TF, van den Ouweland RC, et al. Development and Validation of a Disease‐Specific Questionnaire to Assess Patient‐Reported Symptoms in Polycystic Liver Disease. Hepatology (Baltimore, Md). 2016;64(1):151‐60. doi: 10.1002/hep.28545;

D'Agnolo HM, Drenth JP. Risk factors for progressive polycystic liver disease: where do we stand? Nephrology, dialysis, transplantation:2016;31(6):857‐9 10.1093/ndt/gfv417;

D'Agnolo HM, Kievit W, Takkenberg RB, Riano I, Bujanda L, Neijenhuis MK, et al. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial. Journal of hepatology. 2016;65(3):601‐7;

Leonhard,W.N., Kunnen,S.J., Plugge,A.J., Pasternack,A., Jianu,S.B., Veraar,K., El,B.F., Hoogaars,W.M., ten,D.P., Breuning,M.H., et al. (2016) Inhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease. J. Am.Soc. Nephrol. 2016 Dec;27(12):3589‐3599. DOI:10.1681/ASN.2015030287;;

Zittema,D., Versteeg,I.B., Gansevoort,R.T., van,G.H., de,H.E., Veraar,K.A., Peters,D.J., Meijer,E. (2016) DoseTitrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease. Am. J. Nephrol., 44, 194‐203. DOI: 10.1159/000448693

M.D.A. van Gastel, A.L. Messchendorp, P. Kappert, M.A. Kaatee, M. de Jong, R.J. Renken, G.J. ter Horst, S.V.K. Mahesh, R.T. Gansevoort. T1 vs. T2 weighted magnetic resonance imaging to assess total kidney volume in patients with autosomal dominant polycystic kidney disease. Abdom Radiol. 2017. DOI: 10.1007/s00261‐017‐1285‐2‐017‐1285‐2 WP2

Casteleijn,N.F., van Gastel,M.D., Blankestijn,P.J., Drenth,J.P., de Jager,R.L., Leliveld,A.M., Stellema,R., Wolff,A.P., Groen,G.J., Gansevoort,R.T. (2017) Novel treatment protocol for ameliorating refractory, chronic pain in patients with autosomal dominant polycystic kidney disease. Ki, 91, 972‐981. DOI: 10.1016/j.kint.2016.12.007

Lantinga,M.A., D'Agnolo,H.M., Casteleijn,N.F., de Fijter,J.W., Meijer,E., Messchendorp,A.L., Peters,D.J., Salih,M., Spithoven,E.M., Soonawala,D., et al. (2017) Hepatic Cyst Infection During Use of the Somatostatin Analog. Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open‐Label Multicenter DIPAK‐1 Study. Drug Saf, 40, 153‐167. doi: 10.1007/s40264‐016‐0486‐x

Lantinga,M.A., Casteleijn,N.F., Geudens,A., de Sevaux,R.G., van Assen,S., Leliveld,A.M., Gansevoort,R.T., Drenth,J.P. (2017) Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review. Nephrol. Dial. Transplant., 32, 144‐150. DOI 10.1093/ndt/gfv452 Open Access No WP3

Versteeg,I.B., Casteleijn,N.F., Gansevoort,R.T. (2017) Transcatheter arterial embolization: an underappreciated alternative to nephrectomy in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant. 2017 Jul 1;32(7):1075‐1078. DOI: 10.1093/ndt/gfx056.

Borras,D.M., Vossen,R., Liem,M., Buermans,H.P., Dauwerse,H., van,H.D., Gansevoort,R.T., den Dunnen,J.T., Janssen,B., Peters,D.J., et al. (2017) Detecting PKD1 variants in polycystic kidney disease patients by singlemolecule long‐read sequencing. Hum. Mutat., Jul;38(7):870‐879. doi: 10.1002/humu.23223

Sánchez‐López E, Happé H, Steenvoorden E, Crego AL, Marina ML, Peters DJM, Mayboroda OA.(2017) A crossplatform metabolomics workflow for volume‐restricted tissue samples: application to an animal model for polycystic kidney disease. Mol Biosyst., Sep 26;13(10):1940‐1945. doi: 10.1039/c7mb00245a.

H.M. D’Agnolo*, N.F. Casteleijn*, T.J. Gevers, H. de Fijter, M.D. van Gastel, A.L. Messchendorp, D.J. Peters, M. Salih, E.M. Spithoven, D. Soonawala, F.W. Visser, J. Wetzels, B. Zietse, R.T. Gansevoort, J.P. Drenth, on behalf of the DIPAK Consortium. * both authors contributed equally. The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.Am J Nephrol. 2017;46(3):239‐248. doi: 10.1159/000479436. Epub 2017 Sep 8.

D'Agnolo HM, Kievit W, van Munster KN, van der Laan JJ, Nevens F, Drenth JP. Center is an important indicator for choice of invasive therapy in polycystic liver disease. Transpl Int. 2017 Jan;30(1):76‐82. doi: 10.1111/tri.12875

Leonhard WN, Happe H, Peters DJ. Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context. J Am Soc Nephrol. 2016 Dec;27(12):3530‐3538. DOI: 10.1681/ASN.2016040425 ;

M. Salih, D.M. Bovee, L.C. Roksnoer, N.F. Casteleijn, S.J. Bakker, R.T. Gansevoort, R. Zietse, A.H. Danser, E.J. Hoorn, on behalf of the DIPAK consortium, Urinary Renin‐Angiotensin Markers in Polycystic Kidney Disease. Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F874‐F881. DOI: 10.1152/ajprenal.00209.2017; ;

Neijenhuis MK, Kievit W, Perrone RD, Sloan JA, Erwin P, Murad MH, Gevers TJG, Hogan MC, Drenth JPH. The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta‐analysis and meta‐regression. BMC Nephrol. 2017 May 25;18(1):169. DOI: 10.1186/s12882‐017‐0578‐6.

van Aerts RMM, van de Laarschot LFM, Banales JM, Drenth JPH. Clinical management of polycystic liver disease. J Hepatol. 2017 Nov 24. pii: S0168‐8278(17)32449‐2. doi: 10.1016/j.jhep.2017.11.024.

A.L. Messchendorp, E. Meijer, W.E. Boertien, G.E. Engels, N.F. Casteleijn, E.M. Spithoven, M. Losekoot, J.G.M. Burgerhof, D.J.M. Peters, R.T. Gansevoort, on behalf of the DIPAK consortium. Urinary biomarkers to identify Autosomal Dominant Polycystic Kidney Disease patients with a high likelihood of disease progression. KI reports. 2018 Mar. 2(3):291‐301. DOI: 10.1016/j.ekir.2017.10.004.

Neijenhuis MK, Kievit W, Verheesen SM, D'Agnolo HM, Gevers TJ, Drenth JP. Impact of liver volume on polycystic liver disease‐related symptoms and quality of life United European Gastroenterol J. 2018 Feb;6(1):81‐88. doi: 10.1177/2050640617705577.

Lin C, Happé H, Veraar K, Scharpfenecker M, Peters DJ; Dipak Consortium. The expression of somatostatin receptor 2 decreases during cyst growth in mice with polycystic kidney disease. Exp Biol Med (Maywood). 2018 Sep;243(13):1092‐1098. doi: 10.1177/1535370218803893.‐2003&

Messchendorp AL, Spithoven EM, Casteleijn NF, Dam WA, van den Born J, Tonnis WF, Gaillard CAJM, Meijer E; DIPAK Consortium. BMC Nephrol. 2018 Dec 19;19(1):368. doi: 10.1186/s12882‐018‐1176‐y.‐018‐1176‐y1.‐018‐1176‐y;

Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D'Agnolo HMA, Dekker SEI, Drenth JPH, de Fijter JW, van Gastel MDA, Gevers TJ, Lantinga MA, Losekoot M, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Wetzels JF, Zietse R, Gansevoort RT; DIPAK‐1 Investigators. Effect of Lanreotide on KidneyFunction in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial. JAMA. 2018 Nov 20;320(19):2010‐2019. doi: 10.1001/jama.2018.15870.

van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M, Meijer E, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Drenth JPH; DIPAK-1 Investigators. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. Gastroenterology. 2019 Apr 22. pii: S0016-5085(19)36711-3. doi: 10.1053/j.gastro.2019.04.018